Cita APA

Bota, D., Desjardins, A., Mason, W., Kesari, S., Magge, R., Winograd, B., . . . Trikha, M. (2017). ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM). Neuro Oncol.

Chicago Style Citation

Bota, Daniela, Annick Desjardins, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Steven D. Reich, Nancy Levin, i Mohit Trikha. "ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)." Neuro Oncol 2017.

Cita MLA

Bota, Daniela, et al. "ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)." Neuro Oncol 2017.